Qinwei Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qinwei Yu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Zhenzhou Jiang
New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
26 shared publications - Luyong Zhang
New Drug Screening and Pharmacodynamics Evaluation Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
13 shared publications Qian Lu
New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
9 shared publicationsXue Fan
New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
8 shared publicationsLuyong Zhang
New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China
7 shared publicationsJie Wang
New Drug Screening and Pharmacodynamics Evaluation Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China
6 shared publications
Latest Publications
- 26 June 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (18) , 5496-5515
Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy
Background and Purpose: Duchenne muscular dystrophy (DMD) is an X‐linked recessive disorder caused by dystrophin gene mutations. This study investigated the therapeutic effects of leflunomide, a STAT1 inhibitor on dystrophic muscles. Experimental Design: The characterization of M1 macrophage polarization and the level of STAT1/ p ‐STAT1 were measured in DMD patients. Lipopolysaccharide (LPS)/IFN‐γ and RO8191 were selected to stimulate STAT1 for evaluating the inhibitory effect of A771726 on M1 polarization and STAT1. Conditionally cocultured M1 RAW264.7 cells and differentiated C2C12 myoblasts were used to explore the differentiation of A771726 to myopathy in inflammatory environments. After 4‐week treatment with leflunomide, the protein levels of STAT1 and p ‐STAT1 were evaluated in mdx mice. CD86 and CD68 were selected for evaluating inflammation event. The proinflammatory cytokines were measured by RT‐PCR and ELISA. Muscle function and myofibre damage were examined by behavioural experiments and serum CK and LDH level, respectively. The muscle regeneration event was demonstrated by myosin heavy chain, myogenic differentiation (MyOD) protein levels and eMyHC immunofluorescence. Key Results: STAT1 was remarkably upregulated in mdx mice and DMD patients compared with control groups. A771726 restrained LPS/IFN‐γ‐induced M1 macrophage polarization via inhibiting p ‐STAT1 and STAT1. Specific activation of STAT1 by RO8191 promoted macrophage polarize towards M1 type, which was partially counteracted by A771726. Leflunomide‐inhibited inflammation infiltration mediated by M1 macrophage and exerted promising therapeutic effect on muscle repair in mdx mice. Conclusions and Implications: Leflunomide relieved M1 macrophage infiltration and improved muscle regeneration by downregulating STAT1 and p ‐STAT1. STAT1 may merge as a promising target for the therapy of DMD.
- 26 June 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (18) , 5496-5515
Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy
Background and Purpose: Duchenne muscular dystrophy (DMD) is an X‐linked recessive disorder caused by dystrophin gene mutations. This study investigated the therapeutic effects of leflunomide, a STAT1 inhibitor on dystrophic muscles. Experimental Design: The characterization of M1 macrophage polarization and the level of STAT1/ p ‐STAT1 were measured in DMD patients. Lipopolysaccharide (LPS)/IFN‐γ and RO8191 were selected to stimulate STAT1 for evaluating the inhibitory effect of A771726 on M1 polarization and STAT1. Conditionally cocultured M1 RAW264.7 cells and differentiated C2C12 myoblasts were used to explore the differentiation of A771726 to myopathy in inflammatory environments. After 4‐week treatment with leflunomide, the protein levels of STAT1 and p ‐STAT1 were evaluated in mdx mice. CD86 and CD68 were selected for evaluating inflammation event. The proinflammatory cytokines were measured by RT‐PCR and ELISA. Muscle function and myofibre damage were examined by behavioural experiments and serum CK and LDH level, respectively. The muscle regeneration event was demonstrated by myosin heavy chain, myogenic differentiation (MyOD) protein levels and eMyHC immunofluorescence. Key Results: STAT1 was remarkably upregulated in mdx mice and DMD patients compared with control groups. A771726 restrained LPS/IFN‐γ‐induced M1 macrophage polarization via inhibiting p ‐STAT1 and STAT1. Specific activation of STAT1 by RO8191 promoted macrophage polarize towards M1 type, which was partially counteracted by A771726. Leflunomide‐inhibited inflammation infiltration mediated by M1 macrophage and exerted promising therapeutic effect on muscle repair in mdx mice. Conclusions and Implications: Leflunomide relieved M1 macrophage infiltration and improved muscle regeneration by downregulating STAT1 and p ‐STAT1. STAT1 may merge as a promising target for the therapy of DMD.
- 6 January 2026
- Published by Elsevier in Cellular Signalling
- Vol. 139, 112357
Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice
- 6 January 2026
- Published by Elsevier in Cellular Signalling
- Vol. 139, 112357
Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice
- 16 September 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111752
Obeticholic acid exacerbates liver injury through hepatocyte-mediated release of HMGB1 by inducing lysosomal membrane permeabilization in cholestasis
- 16 September 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111752
Obeticholic acid exacerbates liver injury through hepatocyte-mediated release of HMGB1 by inducing lysosomal membrane permeabilization in cholestasis
- 14 June 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 68, 679-690
Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses
- 14 June 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 68, 679-690
Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses
- 16 May 2025
- Published by Elsevier in Molecular Pharmacology
- Vol. 107 (7) , 100047
Fenofibrate promotes erucic acid metabolism by peroxisome enzyme EHHADH activation alleviating high-fat diet–induced steatotic liver disease
- 16 May 2025
- Published by Elsevier in Molecular Pharmacology
- Vol. 107 (7) , 100047
Fenofibrate promotes erucic acid metabolism by peroxisome enzyme EHHADH activation alleviating high-fat diet–induced steatotic liver disease
- 13 May 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1000, 177730
Immune-endothelial cell crosstalk in hepatic endothelial injury of liver fibrotic mice
- 13 May 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1000, 177730
Immune-endothelial cell crosstalk in hepatic endothelial injury of liver fibrotic mice
- Open Access
- 21 April 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (2) , e13807
Oestrogen Receptor Alpha in Myocyte Maintains Muscle Regeneration in Duchenne Muscular Dystrophy
Background: Oestrogen receptor alpha (ERα) plays an important role in maintaining mitochondrial function and regulating metabolism in skeletal muscle. However, its alterations and potential mechanisms in Duchenne muscular dystrophy (DMD) remain incompletely understood. In this study, we demonstrated the protective role of ERα in myocyte for skeletal muscle regeneration in mdx mice and explored the therapeutic effects of oestrogen receptor modulators on DMD. Methods: DMD patients' biopsies were obtained for histological analysis to explore the expression of ERα. The phenotype of muscle was analysed by histology and molecular biology. The therapeutical effect of different oestrogen receptor modulators was examined in mdx mice treated with fulvestrant (FVT, 20 mg/kg once a week) or oestradiol (E2, 1 mg/kg per day) for 4 weeks. The protective effect of ERα was performed on mdx mice after conditional knockout of ERα in skeletal muscle (ERα mKO mdx mice). Evidence of activation of ERα/oestrogen‐related receptor alpha (ERRα)/myogenic differentiation 1 (MyoD) signalling pathway was inspected in the primary myoblasts isolated from mice, and C2C12 cells received intervention with E2/FVT/ Esr1 ‐siRNA/ Esrra overexpression plasmid. Results: The ERα expression was increased in DMD patients' triceps ( p < 0.05) and mdx mice muscles ( p < 0.05). FVT reduced ERα levels in the mdx mice muscles ( p < 0.01) but had no significant effect on skeletal muscle regeneration on mdx mice. Compared with mdx mice, E2 reduced the levels of creatine kinase (CK) and lactic dehydrogenase (LDH) ( p < 0.001) in serum, enhanced skeletal muscle function, alleviated skeletal muscle atrophy and fibre loss and upregulated the expression of ERα in GAS ( p < 0.001) and TA ( p < 0.05). The myogenic factors such as myosin heavy chain (MyHC, p < 0.001), myogenin (MyoG, p < 0.05), MyoD ( p < 0.05) and ERRα ( p < 0.001) were increased in mdx mice GAS with E2. But E2 had no effect on ERα mKO mdx mice. The primary myoblasts and C2C12 were treated with E2 displayed an increased‐on myocyte fusion index ( p < 0.05), ERα MyoD and ERRα expressions ( p < 0.05). The myocytes' fusion index ( p < 0.05) and ERα, MyoD and ERRα expression ( p < 0.05) were decreased in si‐ Esr1 ‐transfected C2C12 cells and increased in OE‐ Esrra ‐transfected C2C12 cells. Conclusion: We demonstrated that ERα in myocyte exerted a protective effect on skeletal muscle regeneration in DMD patients and mdx mice through the ERα‐ERRα‐MyoD pathway, which has potential implications for DMD therapy strategies.
- 21 April 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (2) , e13807
Open AccessOestrogen Receptor Alpha in Myocyte Maintains Muscle Regeneration in Duchenne Muscular Dystrophy
Background: Oestrogen receptor alpha (ERα) plays an important role in maintaining mitochondrial function and regulating metabolism in skeletal muscle. However, its alterations and potential mechanisms in Duchenne muscular dystrophy (DMD) remain incompletely understood. In this study, we demonstrated the protective role of ERα in myocyte for skeletal muscle regeneration in mdx mice and explored the therapeutic effects of oestrogen receptor modulators on DMD. Methods: DMD patients' biopsies were obtained for histological analysis to explore the expression of ERα. The phenotype of muscle was analysed by histology and molecular biology. The therapeutical effect of different oestrogen receptor modulators was examined in mdx mice treated with fulvestrant (FVT, 20 mg/kg once a week) or oestradiol (E2, 1 mg/kg per day) for 4 weeks. The protective effect of ERα was performed on mdx mice after conditional knockout of ERα in skeletal muscle (ERα mKO mdx mice). Evidence of activation of ERα/oestrogen‐related receptor alpha (ERRα)/myogenic differentiation 1 (MyoD) signalling pathway was inspected in the primary myoblasts isolated from mice, and C2C12 cells received intervention with E2/FVT/ Esr1 ‐siRNA/ Esrra overexpression plasmid. Results: The ERα expression was increased in DMD patients' triceps ( p < 0.05) and mdx mice muscles ( p < 0.05). FVT reduced ERα levels in the mdx mice muscles ( p < 0.01) but had no significant effect on skeletal muscle regeneration on mdx mice. Compared with mdx mice, E2 reduced the levels of creatine kinase (CK) and lactic dehydrogenase (LDH) ( p < 0.001) in serum, enhanced skeletal muscle function, alleviated skeletal muscle atrophy and fibre loss and upregulated the expression of ERα in GAS ( p < 0.001) and TA ( p < 0.05). The myogenic factors such as myosin heavy chain (MyHC, p < 0.001), myogenin (MyoG, p < 0.05), MyoD ( p < 0.05) and ERRα ( p < 0.001) were increased in mdx mice GAS with E2. But E2 had no effect on ERα mKO mdx mice. The primary myoblasts and C2C12 were treated with E2 displayed an increased‐on myocyte fusion index ( p < 0.05), ERα MyoD and ERRα expressions ( p < 0.05). The myocytes' fusion index ( p < 0.05) and ERα, MyoD and ERRα expression ( p < 0.05) were decreased in si‐ Esr1 ‐transfected C2C12 cells and increased in OE‐ Esrra ‐transfected C2C12 cells. Conclusion: We demonstrated that ERα in myocyte exerted a protective effect on skeletal muscle regeneration in DMD patients and mdx mice through the ERα‐ERRα‐MyoD pathway, which has potential implications for DMD therapy strategies.
- Open Access
- 13 March 2025
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (3) , 652-666
LncRNA Gm35585 transcriptionally activates the peroxidase EHHADH against diet-induced fatty liver
Metabolic-dysfunction-associated steatotic liver disease is one of the most common chronic liver diseases worldwide and has no approved treatment thus far. Here we report that the hepatic overexpression of Gm35585, a novel lncRNA downregulated in the livers of mice fed a high-fat diet, is functionally important in alleviating hepatic lipid accumulation pathologies. Gm35585 activates the peroxisome proliferator-activated receptor α (PPARα) signaling pathway and promotes the expression of downstream PPARα-target gene, enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (EHHADH), which is one of the four enzymes of the peroxisomal β-oxidation pathway. Activation of EHHADH promotes the oxidation of long-chain fatty acids (LCFAs), and the increased levels of hepatic LCFAs contribute to metabolic-dysfunction-associated steatotic liver disease. Mechanistically, Gm35585 binds to retinoid X receptor α (RXRα) and then forms a PPARα/RXRα heterodimer with PPARα and guides the heterodimer to recognize the promoter of EHHADH, which is called peroxisome proliferator-activated receptor response element, causing transcriptional activation of EHHADH. Taken together, Gm35585 is a hepatic lipid metabolism regulator that activates EHHADH transcription, promoting peroxisomal β-oxidation of LCFAs and ultimately ameliorating diet-induced fatty liver.
- 13 March 2025
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (3) , 652-666
Open AccessLncRNA Gm35585 transcriptionally activates the peroxidase EHHADH against diet-induced fatty liver
Metabolic-dysfunction-associated steatotic liver disease is one of the most common chronic liver diseases worldwide and has no approved treatment thus far. Here we report that the hepatic overexpression of Gm35585, a novel lncRNA downregulated in the livers of mice fed a high-fat diet, is functionally important in alleviating hepatic lipid accumulation pathologies. Gm35585 activates the peroxisome proliferator-activated receptor α (PPARα) signaling pathway and promotes the expression of downstream PPARα-target gene, enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (EHHADH), which is one of the four enzymes of the peroxisomal β-oxidation pathway. Activation of EHHADH promotes the oxidation of long-chain fatty acids (LCFAs), and the increased levels of hepatic LCFAs contribute to metabolic-dysfunction-associated steatotic liver disease. Mechanistically, Gm35585 binds to retinoid X receptor α (RXRα) and then forms a PPARα/RXRα heterodimer with PPARα and guides the heterodimer to recognize the promoter of EHHADH, which is called peroxisome proliferator-activated receptor response element, causing transcriptional activation of EHHADH. Taken together, Gm35585 is a hepatic lipid metabolism regulator that activates EHHADH transcription, promoting peroxisomal β-oxidation of LCFAs and ultimately ameliorating diet-induced fatty liver.
- 24 December 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 406, 111364
Obeticholic acid aggravates liver fibrosis by activating hepatic farnesoid X receptor-induced apoptosis in cholestatic mice
- 24 December 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 406, 111364
Obeticholic acid aggravates liver fibrosis by activating hepatic farnesoid X receptor-induced apoptosis in cholestatic mice
- Open Access
- 17 October 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (10) , 556
Silybin Meglumine Mitigates CCl4-Induced Liver Fibrosis and Bile Acid Metabolism Alterations
Background: Altered patterns of bile acids (BAs) are frequently present in liver fibrosis, and BAs function as signaling molecules to initiate inflammatory responses. Silybin meglumine (SLB-M) is widely used in treating various liver diseases including liver fibrosis. However, research on its effects on bile acid (BA) metabolism is limited. This study investigated the therapeutic effects of SLB-M on liver fibrosis and BA metabolism in a CCl4-induced murine model. Methods: A murine liver fibrosis model was induced by CCl4. Fibrosis was evaluated using HE, picrosirius red, and Masson’s trichrome staining. Liver function was assessed by serum and hepatic biochemical markers. Bile acid (BA) metabolism was analyzed using LC-MS/MS. Bioinformatics analyses, including PPI network, GO, and KEGG pathway analyses, were employed to explore molecular mechanisms. Gene expression alterations in liver tissue were examined via qRT-PCR. Results: SLB-M treatment resulted in significant histological improvements in liver tissue, reducing collagen deposition and restoring liver architecture. Biochemically, SLB-M not only normalized serum liver enzyme levels (ALT, AST, TBA, and GGT) but also mitigated disruptions in both systemic and hepatic BA metabolism by increased unconjugated BAs like cholic acid and chenodeoxycholic acid but decreased conjugated BAs including taurocholic acid and taurodeoxycholic acid, compared to that in CCl4-induced murine model. Notably, SLB-M efficiently improved the imbalance of BA homeostasis in liver caused by CCl4 via activating Farnesoid X receptor. Conclusions: These findings underscore SLB-M decreased inflammatory response, reconstructed BA homeostasis possibly by regulating key pathways, and gene expressions in BA metabolism.
- 17 October 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (10) , 556
Open AccessSilybin Meglumine Mitigates CCl4-Induced Liver Fibrosis and Bile Acid Metabolism Alterations
Background: Altered patterns of bile acids (BAs) are frequently present in liver fibrosis, and BAs function as signaling molecules to initiate inflammatory responses. Silybin meglumine (SLB-M) is widely used in treating various liver diseases including liver fibrosis. However, research on its effects on bile acid (BA) metabolism is limited. This study investigated the therapeutic effects of SLB-M on liver fibrosis and BA metabolism in a CCl4-induced murine model. Methods: A murine liver fibrosis model was induced by CCl4. Fibrosis was evaluated using HE, picrosirius red, and Masson’s trichrome staining. Liver function was assessed by serum and hepatic biochemical markers. Bile acid (BA) metabolism was analyzed using LC-MS/MS. Bioinformatics analyses, including PPI network, GO, and KEGG pathway analyses, were employed to explore molecular mechanisms. Gene expression alterations in liver tissue were examined via qRT-PCR. Results: SLB-M treatment resulted in significant histological improvements in liver tissue, reducing collagen deposition and restoring liver architecture. Biochemically, SLB-M not only normalized serum liver enzyme levels (ALT, AST, TBA, and GGT) but also mitigated disruptions in both systemic and hepatic BA metabolism by increased unconjugated BAs like cholic acid and chenodeoxycholic acid but decreased conjugated BAs including taurocholic acid and taurodeoxycholic acid, compared to that in CCl4-induced murine model. Notably, SLB-M efficiently improved the imbalance of BA homeostasis in liver caused by CCl4 via activating Farnesoid X receptor. Conclusions: These findings underscore SLB-M decreased inflammatory response, reconstructed BA homeostasis possibly by regulating key pathways, and gene expressions in BA metabolism.